|
|
|
|
|
03.06.26 - 14:03
|
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions (GlobeNewswire EN)
|
|
|
NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the National Lipid Association (NLA) 2026 Scientific Sessions, taking place on June 11 – 14, 2026 in Chicago, Illinois....
|
|
|
|
|
|
|
|
|
|
|
|
|
02.06.26 - 09:51
|
QIAGEN Buy (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass Qiagens Tuberkulose-Bluttest Quantiferon nach wie ......
|
|
|
02.06.26 - 08:33
|
Nanobiotix Joins the Euronext Tech Leaders Index (GlobeNewswire EN)
|
|
|
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced its inclusion in the Euronext Tech Leaders segment and Euronext Tech Leaders Index, a Euronext flagship initiative dedicated to increasing the visibility and attractiveness of Europe's leading and high-growth technology companies among international investors....
|
|
|
|
|
|
|
01.06.26 - 14:03
|
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, June 1, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced extended data from the ongoing Phase 1b clinical trial evaluating anzu-cel (anzutresgene autoleucel, IMA203) PRAME TCR T-cell therapy in heavily pretreated patients with advanced melanoma in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, USA. The dataset is focused on patients treated with anzu-cel at the recommended Phase 2 dose (RP2D), including longer follow-up and further characterization of the durability and systemic nature of the observed clinical responses....
|
|
|
01.06.26 - 07:03
|
IBA launches Cyclone® iKure, a cyclotron designed for industrial scale Astatine-211 production (GlobeNewswire EN)
|
|
|
Louvain-la-Neuve, Belgium – 01 June 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today launches Cyclone® iKure, a dedicated cyclotron for routine Astatine-211 (At-211) production. Designed for alpha-beam irradiation, this new cyclotron enables radiopharmaceutical manufacturers, research institutions and healthcare providers to accelerate access to targeted alpha therapies with the reliability and quality required for clinical-scale programs....
|
|
|
31.05.26 - 15:03
|
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, May 31, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced the presentation of extended data from the ongoing Phase 1 clinical trial evaluating its TCR bispecific (TCER®) candidate IMA401 targeting MAGEA4/8 in heavily pretreated patients with solid tumors, including head and neck cancer and lung cancer, in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA. The data show a consistent and favorable tolerability profile across multiple tumor types and encouraging anti-tumor activity at the recommended Phase 2 dose (RP2D) with or without the immune checkpoint inhibitor (ICI) pembrolizumab. Results from the Phase 1 study are being published simultaneously in Nature Medicine....
|
|
|
30.05.26 - 14:03
|
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting (GlobeNewswire EN)
|
|
|
Houston, Texas and Tuebingen, Germany, May 30, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy in gynecologic cancers and synovial sarcoma at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA. One-time infusion of IMA203CD8 demonstrated meaningful clinical activity across different tumor types as well as manageable tolerability. The broad expression of PRAME in more than 50 cancers further supports the continued development of IMA203CD8 in multiple PRAME-positive solid tumors....
|
|
|
30.05.26 - 09:36
|
ANLEIHEN-Woche #KW22 – 2026: PNE, Iute, reconcept, EPH, Singulus, Photon Energy, LAIQON, Tempton, BOOSTER, Energiekontor, Südzucker, HÖRMANN, DEAG, HMS Bergbau, PORR, Formycon, PCC, Circus, TPG, … (Anleihen-Finder)
|
|
|
Ereignisreiche Woche am KMU-Anleihemarkt Die PNE AG treibt in der Kalenderwoche 22 die Platzierung ihrer neuen Unternehmensanleihe 2026/31 (ISIN: DE000A460J75) planmäßig voran. Seit dieser Woche […]
Der Beitrag ANLEIHEN-Woche #KW22 – 2026: PNE, Iute, reconcept, EPH, Singulus, Photon Energy, LAIQON, Tempton, BOOSTER, Energiekontor, Südzucker, HÖRMANN, DEAG, HMS Bergbau, PORR, Formycon, PCC, Circus, TPG, … erschien zuerst auf Anleihen-Finder.de....
|
|
|
29.05.26 - 19:06
|
′Hardware is sexy again′: Plug and Play CEO says AI boom has finally fulfilled his 2006 semiconductor dream (Digitimes)
|
|
|
The building where Saeed Amidi runs his global venture empire was once one of the most important semiconductor facilities on the West Coast. Philips Electronics operated a fabrication plant here in Sunnyvale, California, employing 8,000 people at its peak. Then, like much of America's chip manufacturing base, it moved to Asia — to Taiwan, to Korea, to the supply chains that would come to define the global electronics industry for the next three decades....
|
|
|
|
|
|
|
29.05.26 - 12:54
|
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026 (GlobeNewswire EN)
|
|
|
ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026, to be held from June 12-15, 2026, in Istanbul, Turkey....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
